PlasmaTech Biopharmaceuticals Inc (NASDAQ:PTBI), a biopharmaceutical company focused on advancing cell therapy and gene therapy for rare diseases, announced that Todd Wider, MD has been elected to the Company’s Board of Directors. Dr. Wider has a strong medical background and significant experience in small and mid-cap biotechnology companies.
“We are extremely pleased to be able to add Todd to our board of directors,” said Steven H. Rouhandeh, the Company’s Executive Chairman. “Todd brings to the board a unique blend of skills and experience that will be of great value to the Company as we continue to build out our product pipeline in cell and gene therapies focused on rare diseases.”
Todd Wider graduated with high honors from Princeton University, and earned his MD from Columbia College of Physicians and Surgeons. In addition to his surgical experience, Dr. Wider has extensive experience in the biotechnology investment community and has been a consultant to leading healthcare institutional investors for years. His experience includes public and private financings, corporate development and licensing transactions in the biotechnology and medical device industries. (Original Source)
Shares of Plasmatech Biopharmaceuticals opened today at $7.99 and are currently trading down at $7.88. PTBI has a 1-year high of $8.44 and a 1-year low of $2.88. The stock’s 50-day moving average is $4.33 and its 200-day moving average is $4.76.